Kura Oncology Inc

Stock Chart, Company Information, and Scan Results

$8.39(as of Sep 25, 10:26 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kura Oncology Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$8.39
Ticker SymbolKURA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees192
CountyUSA
Market Cap$715.2M
EBIDTA-218.8M
10-Day Moving Average8.31
P/E Ratio-3.72
20-Day Moving Average8.20
Forward P/E Ratio0.00
50-Day Moving Average7.22
Earnings per Share-2.25
200-Day Moving Average7.20
Profit Margin-432.51%
RSI58.40
Shares Outstanding86.8M
ATR0.46
52-Week High19.94
Volume1,344,274
52-Week Low5.41
Most Recent Support Level8.04
Book Value305.5M
Most Recent Resistance Level8.57
P/B Ratio2.40
Upper Keltner9.24
P/S Ratio8.81
Lower Keltner7.15
Debt-to-Equity Ratio9.24
Next Earnings Date10/30/2025
Cash Surplus-25.2M
Next Ex-Dividend DateUnknown

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.

Kura Oncology Inc In Our Stock Scanner

As of Sep 25, 2025
example chart graphic
Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Channel Pattern RangeScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.